IMM — ImmuPharma Share Price
Last trade - 00:00- £14.58m
- £13.49m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 5.42 | ||
| Price to Tang. Book | 6.53 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | -208.34 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -93.97% | ||
| Return on Equity | -111.2% | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | £m | 0.08 | 0.13 | 0.12 | n/a | n/a | n/a | n/a | -100% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
ImmuPharma PLC is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company is focused on developing peptide bio-drugs in specialty therapeutic areas. Its portfolio includes peptide therapeutics for autoimmune diseases and anti-infectives. Its lead program, P140 (Lupuzor), is an autophagy immunomodulator for the treatment of lupus. Its pipeline is focused on two therapeutic areas: autoimmunity/inflammation and anti-infectives. Its pipeline products in autoimmunity and inflammation therapeutic area includes Lupuzor and P140 for CIDP. Its pipeline products in the anti-infectives inflammation therapeutic areas include BioAMB and BioCin. BioAMB, a peptide-based drug that offers a potential improvement on the limiting side effects and poor administration regime of Amphotericin-B (AMB) formulations. BioCin, a peptide-based drug based on an existing antibacterial used in high medical need and in many cases as the last line of defense.
Directors
- Last Annual
- December 31st, 2023
- Last Interim
- June 30th, 2024
- Incorporated
- February 21st, 2000
- Public Since
- October 28th, 2003
- No. of Employees
- 5
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- London Stock Exchange
- Shares in Issue
- 416,437,265
- Address
- One Bartholomew Close, LONDON, EC1A 7BL
- Web
- https://www.immupharma.co.uk/
- Phone
- +44 2071524080
- Contact
- Lisa Baderoon
- Auditors
- CLA Evelyn Partners Limited
Latest News for IMM
Upcoming Events for IMM
Full Year 2024 ImmuPharma PLC Earnings Release
ImmuPharma PLC Annual Shareholders Meeting
Half Year 2025 ImmuPharma PLC Earnings Release
Similar to IMM
4Basebio
London Stock Exchange
Allergy Therapeutics
London Stock Exchange
Arecor Therapeutics
London Stock Exchange
Avacta
London Stock Exchange
Batm Advanced Communications
London Stock Exchange
FAQ
As of Today at 20:15 UTC, shares in ImmuPharma are trading at 3.50p. This share price information is delayed by 15 minutes.
Shares in ImmuPharma last closed at 3.50p and the price had moved by +96.91% over the past 365 days. In terms of relative price strength the ImmuPharma share price has outperformed the FTSE All Share Index by +82.39% over the past year.
The overall consensus recommendation for ImmuPharma is Sell. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreImmuPharma does not currently pay a dividend.
ImmuPharma does not currently pay a dividend.
ImmuPharma does not currently pay a dividend.
To buy shares in ImmuPharma you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of 3.50p, shares in ImmuPharma had a market capitalisation of £14.58m.
Here are the trading details for ImmuPharma:
- Country of listing: United Kingdom
- Exchange: LSE
- Ticker Symbol: IMM
Based on an overall assessment of its quality, value and momentum ImmuPharma is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in ImmuPharma is 2.90p. That is 17.14% below the last closing price of 3.50p.
Analysts covering ImmuPharma currently have a consensus Earnings Per Share (EPS) forecast of for the next financial year.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like ImmuPharma. Over the past six months, its share price has outperformed the FTSE All Share Index by +91.32%.
As of the last closing price of 3.50p, shares in ImmuPharma were trading +54.44% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The ImmuPharma PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at 3.50p.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
ImmuPharma's management team is headed by:
- Timothy McCarthy - NEC
- Timothy Franklin - COO
- Ewa Flynn - SEC
- Franco Di Muzio - NID